Class summary at a glance.

Every drug in the Platelet-reducing Agent class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $7.3Mcombined across class
Total Rx claims: 45K11K unique beneficiaries
Generic mfrs (active): 4across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Anagrelide

Brand: Agrylin · 45K Part D claims (CY24) · 11K beneficiaries · First FDA approval: 1997-03-14

4 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.730

→

Avg plan cost$1.15

Part D spend $7.3M 2× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.